Roth Capital Has Bearish Forecast for TENX FY2028 Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Research analysts at Roth Capital cut their FY2028 earnings per share estimates for shares of Tenax Therapeutics in a research report issued to clients and investors on Wednesday, May 14th. Roth Capital analyst J. Aschoff now expects that the specialty pharmaceutical company will post earnings of $1.92 per share for the year, down from their previous forecast of $1.99. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Roth Capital also issued estimates for Tenax Therapeutics’ FY2029 earnings at $3.23 EPS.

Several other analysts have also recently commented on TENX. StockNews.com began coverage on Tenax Therapeutics in a report on Friday. They set a “sell” rating on the stock. Leerink Partners set a $20.00 target price on Tenax Therapeutics in a report on Monday, March 10th. Finally, William Blair restated an “outperform” rating on shares of Tenax Therapeutics in a report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $18.00.

Tenax Therapeutics Price Performance

Shares of TENX stock opened at $5.89 on Friday. The stock’s fifty day simple moving average is $5.86 and its 200 day simple moving average is $5.91. The firm has a market cap of $24.43 million, a price-to-earnings ratio of -2.38 and a beta of 1.92. Tenax Therapeutics has a one year low of $2.77 and a one year high of $7.89.

Tenax Therapeutics (NASDAQ:TENX) last announced its quarterly earnings results on Wednesday, May 14th. The specialty pharmaceutical company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.20.

Hedge Funds Weigh In On Tenax Therapeutics

Large investors have recently made changes to their positions in the company. Two Sigma Investments LP acquired a new position in shares of Tenax Therapeutics during the fourth quarter valued at $84,000. Geode Capital Management LLC lifted its stake in shares of Tenax Therapeutics by 32.4% during the fourth quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock valued at $151,000 after acquiring an additional 5,964 shares during the period. Millennium Management LLC acquired a new position in shares of Tenax Therapeutics during the fourth quarter valued at $166,000. ADAR1 Capital Management LLC lifted its stake in shares of Tenax Therapeutics by 98.1% during the first quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company’s stock valued at $450,000 after acquiring an additional 34,048 shares during the period. Finally, Janus Henderson Group PLC acquired a new position in shares of Tenax Therapeutics during the fourth quarter valued at $1,026,000. Institutional investors and hedge funds own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.